These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30719631)

  • 1. Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.
    Miller KM; Brenner MJ
    Drugs; 2019 Feb; 79(3):291-302. PubMed ID: 30719631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
    Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy.
    Chi G; Gibson CM; Kalayci A; Cohen AT; Hernandez AF; Hull RD; Kahe F; Jafarizade M; Sharfaei S; Liu Y; Harrington RA; Goldhaber SZ
    Intensive Care Med; 2019 Apr; 45(4):477-487. PubMed ID: 30778649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
    Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
    J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
    Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
    Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
    Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
    Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull RD; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Haemost; 2019 Dec; 17(12):2089-2098. PubMed ID: 31392827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of betrixaban and its role in clinical practice.
    Lekura J; Kalus JS
    Am J Health Syst Pharm; 2018 Aug; 75(15):1095-1102. PubMed ID: 29941506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
    Garland SG; DeRemer CE; Smith SM; Gums JG
    Ann Pharmacother; 2018 Jun; 52(6):554-561. PubMed ID: 29338293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
    Gibson CM; Chi G; Halaby R; Korjian S; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Gold A; Bandman O; Harrington RA; Cohen AT;
    Circulation; 2017 Feb; 135(7):648-655. PubMed ID: 27881569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.
    Cohen AT; Harrington RA; Goldhaber SZ; Hull RD; Wiens BL; Gold A; Hernandez AF; Gibson CM;
    N Engl J Med; 2016 Aug; 375(6):534-44. PubMed ID: 27232649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
    Lee K; Cham S; Lam S
    Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
    Escolar G; Díaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 Aug; 53(8):423-434. PubMed ID: 29119147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
    Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis.
    Laskier V; Guy H; Fisher M; Neuman WR; Bucior I; Cohen AT; Ren S
    J Med Econ; 2019 Oct; 22(10):1063-1072. PubMed ID: 31314619
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial.
    Yee MK; Nafee T; Daaboul Y; Korjian S; AlKhalfan F; Kerneis M; Wiest C; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    J Thromb Thrombolysis; 2018 Jan; 45(1):1-8. PubMed ID: 29188425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
    Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
    Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial.
    Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT
    J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.
    Cohen AT; Harrington R; Goldhaber SZ; Hull R; Gibson CM; Hernandez AF; Kitt MM; Lorenz TJ
    Am Heart J; 2014 Mar; 167(3):335-41. PubMed ID: 24576517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.